Atlas Trials

The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia

Clinical trial NCT05004259 · COMPLETED

Trial details

NCT number
NCT05004259
Sponsor
Dartmouth-Hitchcock Medical Center
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Hemolytic Anemia
Start date
2022-03-21
Primary completion
2024-09-21
Enrollment
2

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.